Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials

• المؤلفون الرئيسيون: Joseph F. Merola (مؤلف), April Armstrong (مؤلف), Saakshi Khattri (مؤلف), So Yeon Paek (مؤلف), Byron Padilla (مؤلف), Cuiyong Yue (مؤلف), Huzefa Photowala (مؤلف), Blair Kaplan (مؤلف), Lars Erik Kristensen (مؤلف)
• التنسيق: كتاب
• منشور في: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

AbstractIn the KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) phase 3 trials, risankizumab demonstrated greater efficacy compared with placebo in patients with active psoriatic arthritis (PsA). This post hoc integrated analysis evaluated achieving the following efficacy outcomes at weeks 24 a...